Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V)

Gene Therapy

Volumn 3, Issue 7, 1996, Pages 635-643

  Pavlovic, J ^a   Nawrath, M ^a   Tu, R ^a   Heinicke, T ^a   Moelling, K ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antitumor immunity; Bystander effect; Ganciclovir; Gene therapy; Thymidine kinase

Indexed keywords

THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL KILLING; CELL TRANSFORMATION; CONTROLLED STUDY; GENE ACTIVATION; GENE MUTATION; GENE THERAPY; GENETIC TRANSFECTION; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR IMMUNITY;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; GANCICLOVIR; GENES, RAS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PLASMIDS; SIMPLEXVIRUS; THYMIDINE KINASE; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; HERPES; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MUS MUSCULUS; ONCOVIRINAE; SIMPLEXVIRUS;

EID: 0029737399     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
2. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
3. Borelli E, Heyman R, Hsi M, Evans RM. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 1988; 85: 7574-7576.
4. Reid R, Eng-Chun M, Eng-Shang H, Topal MD. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. J Biol Chem 1988; 263: 3898-3904.
5. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
6. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
7. Chen S-H et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
8. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of HSVtk gene involves an immune component. Cancer Res 1994; 64: 6228-6234.
9. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
10. Colombo BM et al. The 'bystander effect': association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.
11. Samejima Y, Meruelo D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Ther 1995; 2: 50-58.
12. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following kinase mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
13. Tapscott SJ et al. Gene therapy of rat9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-8189.
14. Chen S-H et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
15. Bos JL. ras Oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
16. McCormick F. ras Oncogenes. In: Weinberg RA (ed). Oncogenes and the Molecular Origins of Cancer. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989, pp 125-145.
17. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
18. McCoy MS, Bargmann CI, Weinberg RA. Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol Cell Biol 1984; 4: 1577-1582.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application for proliferation and cytotoxic assays. J Immunol Meth 1983; 65: 55-63.
20. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth 1986; 89: 271-277.
21. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-990.
22. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
23. Chen C-Y et al. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the bystander effect. Hum Gene Ther 1995; 6: 1467-1476.
24. Marini III FC, Nelson JA, Lapeyre J-N. Assessment of bystander effect potency produced by intratumoral implantation of HSVtk-expressing cells using surrogate marker secretion to monitor tumor growth kinetics. Gene Therapy 1995; 2: 655-659.
25. Littlefield J. The use of drug-resistant markers to study the hybridization of mouse fibroblasts. Exp Cell Res 1966; 41: 190-196.
26. Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with 11-2 gene. J Exp Med 1989; 169: 13-25.
27. Pavlovic J, Zürcher T, Haller O, Staeheli P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 1990; 64: 3370-3375.
28. Cox A, Der CJ. Biological assays for cellular transformation. Meth Enzymol 1994; 278: 277-294.
29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidiniurn thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
30. Lowe SW et al. p53 Status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.